Familial hypercholesterolemia (FH) is one of the commonest monogenic disorders, predominantly inherited as an autosomal dominant trait. When untreated, it results in early coronary heart disease. The vast majority of FH remains undiagnosed in Latvia. The identification and early treatment of affected individuals remain a challenge worldwide. Most cases of FH are caused by mutations in one of four genes, APOB, LDLR, PCSK9, or LDLRAP1. The spectrum of disease-causing variants is very diverse and the variation detection panels usually used in its diagnosis cover only a minority of the disease-causing gene variants. However, DNA-based tests may provide an FH diagnosis for FH patients with no physical symptoms and with no known family history of the disease. Here, we evaluate the use of targeted next-generation sequencing (NGS) to identify cases of FH in a cohort of patients with coronary artery disease (CAD) and individuals with abnormal low-density lipoprotein–cholesterol (LDL–C) levels. We used targeted amplification of the coding regions of LDLR, APOB, PCSK9, and LDLRAP1, followed by NGS, in 42 CAD patients (LDL–C, 4.1–7.2 mmol/L) and 50 individuals from a population-based cohort (LDL–C, 5.1–9.7 mmol/L). In total, 22 synonymous and 31 nonsynonymous variants, eight variants in close proximity (10 bp) to intron–exon boundaries, and 50 other variants were found. We identified four pathogenic mutations (p.(Arg3527Gln) in APOB, and p.(Gly20Arg), p.(Arg350*), and c.1706–10G > A in LDLR) in seven patients (7.6 %). Three possible pathogenic variants were also found in four patients. NGS-based methods can be used to detect FH in high-risk individuals when they do not meet the defined clinical criteria.
Background: There is limited data on the genetic characteristics of patients with familial hypercholesterolemia (FH) in Latvia. We aim to describe monogenic variants in patients from the Latvian Registry of FH (LRFH). Methods: Whole genome sequencing with 30× coverage was performed in unrelated index cases from the LRFH and the Genome Database of Latvian Population. LDLR, APOB, PCSK9, LDLRAP1, ABCG5, ABCG8, LIPA, LPA, CYP27A1, and APOE genes were analyzed. Only variants annotated as pathogenic (P) or likely pathogenic (LP) using the FH Variant Curation Expert Panel guidelines for LDLR and adaptations for APOB and PCSK9 were reported. Results: Among 163 patients, the mean highest documented LDL-cholesterol level was 7.47 ± 1.60 mmol/L, and 79.1% of patients had LDL-cholesterol ≥6.50 mmol/L. A total of 15 P/LP variants were found in 34 patients (diagnostic yield: 20.9%): 14 in the LDLR gene and 1 in the APOB gene. Additionally, 24, 54, and 13 VUS were detected in LDLR, APOB, and PCSK9, respectively. No P/LP variants were identified in the other tested genes. Conclusions: Despite the high clinical likelihood of FH, confirmed P/LP variants were detected in only 20.9% of patients in the Latvian cohort when assessed with genome-wide next generation sequencing.
Background and Objectives: Atrial fibrillation (AF) is a primary cause of cardioembolic stroke (CS). AF-related mortality increased substantially in Eastern Europe in the last decade. While direct oral anticoagulants (DOACs) are effective for stroke prevention, non-adherence is a major clinical problem. This study aimed to investigate real-world DOAC usage among AF patients presenting with stroke and to evaluate the impact of prior DOAC therapy on stroke severity. Materials and Methods: This retrospective study analysed data from CS patients with AF admitted to the two largest Latvian university hospitals from January 2022 to December 2024. Secondly, a propensity-matched analysis was performed on a single-centre cohort to compare outcomes between patients receiving DOAC therapy and those not. Results: Of 2773 patients enrolled, the largest subgroup (45%) consisted of patients with known AF who were not on appropriate anticoagulation therapy before the stroke event. The propensity-matched analysis based on demographics, arrival time, AF type, and CHA 2 DS 2 -VA score (163 patients per group) revealed that patients taking DOACs presented with significantly milder strokes than non-users (mean admission NIHSS: 9.8 vs. 11.6, p=0.009). 40.5% of DOAC users received a reduced DOAC dose, and in 22.1% the DOAC dose was reduced inadequately. Stroke patients on DOAC therapy had significantly larger left atrial volume indices (LAVI) than non-users (56.4 vs. 48.0, respectively; p=0.004). Conclusions: Non-adherence to DOACs represents a substantial contributor to the CS burden. Prior DOAC use is associated with significantly reduced initial stroke severity, highlighting the protective benefit of therapy even when it fails to prevent an event.